There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ObsEva SA (OBSV) and Allogene Therapeutics Inc (ALLO) with bullish sentiments.
ObsEva SA (OBSV)
Wedbush analyst Liana Moussatos reiterated a Buy rating on ObsEva SA today and set a price target of $37. The company’s shares opened today at $13.48.
According to TipRanks.com, Moussatos is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -7.5% and a 35.6% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.
Currently, the analyst consensus on ObsEva SA is a Strong Buy with an average price target of $33.40, representing a 147.8% upside. In a report issued on April 29, H.C. Wainwright also reiterated a Buy rating on the stock with a $44 price target.
See today’s analyst top recommended stocks >>
Allogene Therapeutics Inc (ALLO)
William Blair analyst Raju Prasad maintained a Buy rating on Allogene Therapeutics Inc today. The company’s shares opened today at $29.77.
According to TipRanks.com, Prasad is a 5-star analyst with an average return of 23.5% and a 66.7% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Logicbio Therapeutics Inc, and Global Blood Therapeutics.
Allogene Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $41, representing a 37.7% upside. In a report issued on May 2, Oppenheimer also initiated coverage with a Buy rating on the stock with a $45 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
